FASN expression is purported to be part of the estrogen-driven cellular response that leads to proliferation, and inhibiting FASN in endometrial adenocarcinoma cells acts as an antagonist, reducing E2- and tamoxifen-dependent estrogen receptor (ER) transcriptional activity [62]. The gene discussed is FASN; the disease is endometrium adenocarcinoma.